Year: 2014

A Role for ALDH in the Regulation of Necroptosis in Ovarian Cancer Area of research: Therapeutic Targeting

Epithelial ovarian cancer is a rapidly progressive, highly lethal disease, usually diagnosed at late stage…

Read on

Collagen-Remodeling Genes Provide a Niche for Ovarian Cancer

Ovarian cancer is the number one killer among all gynecologic cancers in women. Although chemotherapy is initially successful in reducing tumor growth, more than 60% of patients experience relapse within the first five years…

Read on

Differential MicroDNA Generation in Ovarian Cancer

DNA is the master code for all processes in the cell, and advances in the sequencing of this code have revealed variations among individuals…

Read on

Mechanism of PARP Inhibitor in Ovarian Cancer Therapy Cancer

Cancer occurs as a result of mutations, or abnormal changes, in the genes responsible for regulating the growth of cells and keeping them healthy. Normal cells encounter numerous DNA damages induced by environmental and internal hazards…

Read on

Targeting Adaptive Changes to anti-VEGF Therapy in Ovarian Cancer

(grant originally made to Hyun Jin Choi, MD) Inhibition of vessel production is a promising therapeutic approach to fighting advanced cancer. But, resistance emerges quickly and new approaches are needed…

Read on

Novel Therapeutic Targets for High-Grade Serous Ovarian Carcinoma

Originally awarded to  Maria Giuseppina Baratta, PhD Ovarian cancer is the leading cause of death from gynecologic malignancy in the U.S…

Read on

Dietary Fat, Cholesterol, and Ovarian Cancer Risk

In 2013, over 20,000 women in the United States will be diagnosed with ovarian cancer and over 14,000 will die of the disease. Only half of women diagnosed with ovarian cancer will live 5 years after their diagnosis…

Read on

P53 Aggregation: a New Target to Combat Ovarian Cancer Platinum-Resistance

Epithelial ovarian cancer (EOC) is the most lethal gynecological malignancy. EOC patients often develop chemoresistance, which inevitably leads to disease progression…

Read on

Adipose Tissue Derived Exosomal miRNAs in Ovarian Cancer Progression

Ovarian cancer usually starts to develop in the fallopian tube or the ovary and later develops a secondary malignant growth in the omentum, which is a layer of fatty tissue surrounds the abdominal organs…

Read on

Targeting Spleen Tyrosine Kinase in Chemoresistant Ovarian Cancer

Ovarian high-grade serous carcinoma (HGSC) is a common and aggressive type of ovarian cancer. It accounts for 70% of overall ovarian cancer deaths and is a key contributor to the low five-year survival rate and overall mortality of ovarian cancer…

Read on